CRINETICS PHARMACEUTICALS IN (CRNX)

Company Profile

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 210 full-time employees. The company went IPO on 2018-07-18. The firm is focused on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company offers a pipeline of oral nonpeptide (small molecule) new chemical entities that target peptide G protein coupled receptors (GPCRs) to treat a variety of rare endocrine diseases. The firm's product candidates include paltusotine and CRN04894. Its paltusotine is in clinical development for the treatment of acromegaly and neuroendocrine tumors complicated by carcinoid syndrome. CRN04894 is in clinical development for diseases of excess adrenocorticotrophic hormone (ACTH), including Cushing's disease and congenital adrenal hyperplasia (CAH). The firm's subsidiary is Crinetics Australia Pty Ltd.

Company Info

CRINETICS PHARMACEUTICALS IN

10222 Barnes Canyon Rd Bldg 2

San Diego CALIFORNIA 92121

P: 18584506464

CEO: R. Scott Struthers

Employees: 210

Website: https://www.crinetics.com/